Weisgraber K H, Rall S C, Innerarity T L, Mahley R W, Kuusi T, Ehnholm C
J Clin Invest. 1984 Apr;73(4):1024-33. doi: 10.1172/JCI111287.
A new apolipoprotein E (apo E) phenotype has been demonstrated in a Finnish hypertriglyceridemic subject (R.M.). At the time of this study, R.M.'s plasma triglyceride and cholesterol levels were 1,021 and 230 mg/dl, respectively. The subject's apo E isoelectric focusing pattern was characterized by two major bands, one in the E3 position and the other in the E1 position. Normally the E1 position is occupied by sialylated derivatives of apo E4, E3, or E2. The E1 band of subject R.M. is not a sialylated form, however, because it was not affected by neuraminidase digestion. The identity of the E1 variant as a genetically determined structure was established by amino acid and partial sequence analyses, confirming that the variant is an example of a previously uncharacterized apo E phenotype, E3/1. Both cysteamine modification and amino acid analysis demonstrated that this variant contains two cysteine residues per mole. Sequence analysis of two cyanogen bromide fragments and one tryptic fragment of the apo E3/1 showed that it differs from E2(Arg158----Cys) at residue 127, where an aspartic acid residue is substituted for glycine. This single amino acid interchange is sufficient to account for the one-charge difference observed on isoelectric focusing gels between E2(Arg158----Cys) and the E1 variant. The variant has been designated E1 (Gly127----Asp, Arg158----Cys). When compared with apo E3, the E1 variant demonstrated reduced ability to compete with 125I-LDL for binding to LDL (apo B,E) receptors on cultured fibroblasts (approximately 4% of the amount of binding of apo E3). This defective binding is similar to that of E2-(Arg158----Cys). Therefore, the binding defect of the variant is probably due to the presence of cysteine at residue 158, rather than aspartic acid at residue 127. In contrast, the apo E3 isoform from this subject demonstrated normal binding activity, indicating that it has a normal structure. In family studies, the vertical transmission of the apo E1 variant has been established. It is not yet clear, however, if the hypertriglyceridemia observed in the proband is associated with the presence of the E1(Gly127----Asp, Arg158----Cys) variant.
在一名芬兰高甘油三酯血症患者(R.M.)中发现了一种新的载脂蛋白E(apo E)表型。在本研究时,R.M.的血浆甘油三酯和胆固醇水平分别为1021和230mg/dl。该患者的apo E等电聚焦图谱有两条主要条带,一条在E3位置,另一条在E1位置。正常情况下,E1位置被apo E4、E3或E2的唾液酸化衍生物占据。然而,患者R.M.的E1条带不是唾液酸化形式,因为它不受神经氨酸酶消化的影响。通过氨基酸和部分序列分析确定了E1变体是一种由基因决定的结构,证实该变体是一种先前未被鉴定的apo E表型E3/1的实例。半胱胺修饰和氨基酸分析均表明,该变体每摩尔含有两个半胱氨酸残基。对apo E3/1的两个溴化氰片段和一个胰蛋白酶片段的序列分析表明,它在第127位残基处与E2(Arg158→Cys)不同,该位置的甘氨酸被天冬氨酸取代。这一单氨基酸交换足以解释在等电聚焦凝胶上观察到的E2(Arg158→Cys)和E1变体之间的一个电荷差异。该变体被命名为E1(Gly127→Asp,Arg158→Cys)。与apo E3相比,E1变体与125I-LDL竞争结合培养成纤维细胞上的LDL(apo B,E)受体的能力降低(约为apo E3结合量的4%)。这种结合缺陷与E2-(Arg158→Cys)相似。因此,该变体的结合缺陷可能是由于第158位残基处存在半胱氨酸,而不是第127位残基处的天冬氨酸。相反,该患者的apo E3同工型表现出正常的结合活性,表明其结构正常。在家族研究中,已证实apo E1变体可垂直遗传。然而,先证者中观察到的高甘油三酯血症是否与E1(Gly127→Asp,Arg158→Cys)变体的存在有关尚不清楚。